Principal Investigator/Program Director:
Meyskens, Frank L.
5P30CA062203-17
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Su, Min-Ying Lydia
Professor of Radiological Sciences
eRA COMMONS USER NAME
MINYSU
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
(if applicable)
YEAR(s)
FIELD OF STUDY
National Taiwan University, Taiwan
B.S.
1986
Physics
University of California-Irvine
Ph.D.
1993
Physics
University of California-Irvine
Postdoc
1995
Radiological Sciences
A. Personal Statement
I am a professor in the Department of Radiological Sciences and Physics at UCI, the director of Tu & Yuen
Center for Functional Onco-Imaging, and the co-director of the Disease Oriented Team (DOT) in Women’s
Cancers at the UC Irvine Comprehensive Cancer Center. I have more than 17 years of experience working on
cancer imaging using dynamic contrast enhancement (DCE-MRI), and have been in charge of the clinical breast
MRI research program at UCI since 1999. I have prospectively accrued more than 900 subjects to participate in
various breast DCE-MRI research studies, including 170 NAC patients. My recent efforts has been on
development of quantitative image analysis algorithms for segmentation and characterization of morphology and
texture of normal tissues and abnormal lesions, and utilizing these imaging biomarkers to build computer-aided
diagnosis systems, e.g. for differentiating between patients with benign and malignant breast lesions, and good
NAC responders vs. poor responders. Many of my group’s papers were published in top Radiology/ Surgery/
Oncology journals, and the findings have frequently been quoted in international conference meetings. As a
member of the Athena breast health network, I am extending my research area to risk assessment and
management. Breast density is known as a strong risk factor for developing cancer. My recent work on
developing quantitative analysis methods for measurement of breast density based on MRI provides a great
foundation for building new risk prediction models that can improve the accuracy of the predicted risk for each
individual woman. I am also working on development of surrogate biomarkers based on the change of breast
density on mammography or MRI for predicting the efficacy of hormonal therapy used for chemoprevention or
adjuvant cancer treatment. In addition to MRI, I am also developing novel molecular imaging technology for
selecting and monitoring of patients for targeted therapy. As the DOT leader, I will coordinate the clinical
research activities with investigators from all programs. Particularly I hope to promote the incorporation of
standard clinical imaging and novel imaging technologies using optical and nuclear medicine-based methods to
open new research areas in woman’s cancer.
B. Positions and Honors.
Positions and Employment
1986–1987
Teaching Assistant, Department of Physics, National Taiwan University, Taipei, Taiwan
1995–2001
Assistant Researcher, Department of Radiological Sciences, Univ. of California Irvine, CA
2001–2001
Associate Researcher, Department of Radiological Sciences, Univ. of California Irvine, CA
2001–2006
Assistant Professor, Department of Radiological Sciences, Univ. of California Irvine, CA
2002–2006
Assistant Professor, Department of Physics, University of California Irvine, Irvine, CA
2006–2008
Associate Professor, Departments of Radiological Sciences and Physics, UC Irvine, CA
2006–2009
Shared Resource Director for In Vivo Functional Onco-Imaging, Chao Family Comprehensive
Cancer Center, University of California, Irvine, CA
2008–
Professor, Departments of Radiological Sciences and Physics, UC Irvine, CA
2009–2011
Co-director of the Optical Imaging and Spectroscopy Program, Chao Family Comprehensive
Cancer Center, University of California, Irvine, CA
2009–2011
Associate Director, Tu & Yuen Center for Functional Onco-Imaging, UC Irvine, CA
2011–
Director of Tu & Yuen Center for Functional Onco-Imaging, UC, Irvine, CA
Other Experience and Professional Memberships
1993–
ISMRM (International Society of Magnetic Resonance in Medicine)
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Meyskens, Frank L.
AAPM (The American Association of Physicists in Medicine)
Principal Investigator/Program Director:
1999–
Honors
1995–1996
1998–2001
5P30CA062203-17
UCI-Markey Program in Human Neurobiology fellowship
Career Development Award from US ARMY Breast Cancer Research Program
C. Selected peer-reviewed publications (from a total of 93).
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Chan S, Su MY, Lei F-J, Wu J-P, Lin M, Nalcioglu O, Feig S, Chen J-H. Menstrual Cycle Related
Fluctuations in Breast Density Measured by 3D MRI. Radiology, E-pub on Aug 30 2011.
Chen JH, Bahri S, Mehta RS, Kuzucan A, Yu HJ, Carpenter PM, Feig S, Lin M, Hsiang DJB, Lane KT,
Butler JA, Nalcioglu O, Su MY. Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy
Using Breast MRI at 3T. Radiology, E-pub on Aug 30 2011.
Lin M, Chan S, Chen JH, Chang D, Nie K, Chen ST, Lin CJ, Shih TC, Nalcioglu O, Su MY. A New Bias
Field Correction Method Combining N3 and FCM for Improved Segmentation of Breast Density on MRI.
Med. Phys. 2011 38(5):
Chen JH, Mehta RS, Baek HM, Nie K, Liu H, Lin MQ, Yu HJ, Nalcioglu O, Su MY. Clinical characteristics
and biomarkers of breast cancer associated with choline concentration measured by 1H MR spectroscopy.
NMR Biomed. 2010 Sep 22. [Epub ahead of print]
Chen JH, Chang YC, Chang D, Wang YT, Nie K, Chang RF, Nalcioglu O, Su MY. Reduction of Breast
Density Following Tamoxifen Treatment Evaluated by 3-D MRI: Preliminary Study. Magnetic Resonance
Imaging, 2010 Sep 8. [Epub ahead of print]
Shih TC, Chen JH, Liu D, Nie K, Sun L, Lin M, Chang D, Nalcioglu O, Su MY. Computational simulation of
breast compression based on segmented breast and fibroglandular tissues on magnetic resonance
images. Phys Med Biol. 2010 Jul 21;55(14):4153-68. (PMCID: 2993491)
Nie K, Chen JH, Chang D, Hsu CC, Nalcioglu O, Su MY. Quantitative Analysis of Breast Parenchymal
Patterns Using 3D Fibroglandular Tissue Segmentation Based on MRI. Med. Phys. 2010 Jan; 37(1):217226. (PMCID: 2801737)
Chen JH, Nie K, Bahri S, Hsu CC, Hsu FT, Shih HN, Lin M, Nalcioglu O, Su MY. Decrease in breast
density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging
evaluation. Radiology 2010 Apr;255(1):44-52. (PMCID: 2843830)
Newell D, Nie K, Chen JH, Hsu CC, Yu HJ, Nalcioglu O, Su MY. Selection of Diagnostic Features on
Breast MRI to Differentiate between Malignant and Benign Lesions using Computed-Aided Diagnosis:
differences in lesions presenting as mass and non-mass-like enhancement. Eur. Radiol. 2010
Apr;20(4):771-81. (PMCID: 2835636)
Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioglu O, Su MY. Predicting Pathological
Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and Quantitative Proton MR
Spectroscopy. Radiology. 2009 Jun;251(3):653-62. (PMCID: 2687529)
Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY. Residual
Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and without
Bevacizumab. Ann Surg Oncol. 2009 Jun;16(6):1619-28. (PMCID: 2786305)
Chen JH, Feig BA, Hsiang DJ, Butler JA, Mehta RS, Bahri S, Nalcioglu O, Su MY. Impact of MRIEvaluated Neoadjuvant Chemotherapy Response on Change of Surgical Recommendation in Breast
Cancer. Ann Surg. 2009 Mar;249(3):448-54. (PMCID: 2789298)
Agrawal G, Su MY, Nalcioglu O, Feig SA, Chen JH. Significance of Breast Lesion Descriptors in the ACR
BI-RADS MRI Lexicon. Cancer. 2009 Apr 1;115(7):1363-80. (PMCID: 2748779)
Nie K, Chen JH, Chan S, Chau MI, Yu HJ, Bahri S, Tseng T, Nalcioglu O, Su MY. Development of A
Quantitative Method for Analysis of Breast Density Based on Three-dimensional Breast MRI. Med. Phys.
2008 Dec;35(12):5253-5262. (PMCID: 2673600)
Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY. MRI evaluation of
pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
Cancer. 2008 Jan 1;112(1):17-26.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director:
Meyskens, Frank L.
5P30CA062203-17
D. Research Support.
Ongoing Research Support
R01 CA127927
Su M-Y (PI)
04/01/2008 – 1/31/2014
NIH/NCI
Prediction of Neoadjuvant Chemo Pathological Response Using MRI Markers
This study will use MRI markers to investigate and compare the response of patients with breast cancer to
neoadjuvant chemotherapy, and hope to identify predictive indicators which may impact future therapy selection
or aid in discovery of new therapeutic drugs.
16GB-0056 (Mentor: Su M-Y, Trainee: Lin M-Q)
7/1/2010 – 6/30/2012
CBCRP
MRI Registration for Therapy Evaluation and Annual Screening
This is a pre-doctoral dissertation award for developing registration methods for breast MRI. The serial MRI
scans of patients undergoing neoadjuvant chemotherapy will be registered to facilitate detection of residual
cancer. Images from women who received annual breast MRI screening will be registered to find the areas of
tissues that show changes for early detection of breast cancer.
F18CP18
Su M-Y (PI)
3/07/2011 – 3/06/2012
An Exploratory, Open Label, Non-randomized, Multi Center Study of [F-18]CP-18
F18RGDK5
Su M-Y (PI)
4/30/2010 – 4/29/2012
UCI-10-17: A Phase II, Open Label, Non-Randomized, Multi-Center, Pilot, Efficacy Study of [F18]RGD K5
Position Emission Tomography (PET) as a Tool to Monitor Response to an Anti-Angiogenic Drug
5P30 CA-62203-16 Meyskens F. (PI)
3/01/2009 – 2/28/2014
University of California-Irvine Cancer Center Support Grant
Role: Co-Director of the Onco-Imaging & Spectroscopy Program
R03 CA136071-01A1 Chen, J-H (PI)
3/1/2009 – 2/28/2012
NIH/NCI
Evaluation of 3D MRI-Based Quantitative Breast Density for Chemoprevention
This study will evaluate the change of breast density analyzed based on MRI during hormonal therapy in premenopausal women treated with Tamoxifen compared to controls. The change of density measured by MRI will
also be compared to the changes measured by mammography.
Role: Co-Investigator
R21/33 CA120175
Gulsen G. (PI)
08/1/07 – 07/31/12
NIH/NCI
Development of A Multi-Modality System for Onco-Imaging
This project will develop a hybrid Near Infrared (NIR) and MRI system with dual function NIR/MR contrast agents to
detect and characterize tumors with a higher sensitivity and specificity than current imaging protocols.
Role: Co-Investigator
R01 HD051852
Sandman C. (PI)
09/15/06 – 07/31/12
NIH/NICHD
Fetal Programming of Early Development
This study will investigate the developmental consequences for children with prenatal exposure to corticotrophinreleasing hormone (CRH). MRI is used to measure brain structural differences in these children.
Role: Co-Investigator
R01 HD050662
Davis E. (PI)
04/15/06 – 03/31/12
NIH/NICHD
Prenatal Glucocorticoids Influence Brain And Behavior
This study will investigate the influence of Prenatal Glucocorticoids on brain development of children with MRI
structural imaging.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director:
Meyskens, Frank L.
5P30CA062203-17
Role: Co-Investigator
UCOP Multicampus (Esserman UC Systemwide PI)
07/01/09-06/30/11
Research Program Initiative
ATHENA Breast Health Network
This project is a University of California (UC) initiative to accelerate advancements in breast cancer prevention,
screening, and treatment named the ATHENA Breast Health Network. Hosted at UC San Francisco, ATHENA
will involve 400,000 women throughout California who will be screened for breast cancer and followed for several
decades through the five UC medical centers at Davis, Irvine, Los Angeles, San Diego, and San Francisco.
Role: UCI Site Investigator
Vons/Safeway Foundation
Esserman (PI)
07/01/10-06/30/15
ATHENA Breast Care Network
Collaboration of five University of California health centers, designed to revolutionize breast cancer care by more
efficiently merging research, technology, financing, and health care delivery in a way to reduce time needed to
translate research findings into patient care.
Role: UCI Site Investigator
Completed Research Support
R21 CA121568
Su M-Y (PI)
08/1/2007 – 07/31/2010
NIH/NCI
Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis
This project will investigate the performance of a combined MRI and DOT (Diffuse Optical Tomography) system
for improving diagnostic specificity of breast cancer.
14GB-0148 (Mentor: Su M-Y, Trainee: Nie Ke)
7/1/2008 – 6/30/2010
CBCRP
Development of a Breast MRI Computer-Aided Diagnosis System
This is a pre-doctoral dissertation award for developing computer algorithms for lesion characterization, and
further to build a computer-aided diagnosis (CAD) system for diagnosis of breast lesions on MRI.
R01 CA114210
Muftuler L.M. (PI)
04/06/05 – 02/28/10
NIH/NCI
In-Vivo Conductivity Imaging of Tumor with MREIT
This project will develop MREIT techniques for breast cancer diagnosis, by measuring conductivity in animal
breast tumor models
Role: Co-Investigator
CBCRP 12IB-0095 Gulsen G. (PI)
07/01/06 – 6/30/08
Combined Imaging Modalities for Breast Cancer
This study will develop a combined human MRI and optical imaging platform, and perform initial clinical testing.
Role: Co-Investigator
DOD BCRP BC051304 Shafiiha R. (PI)
05/19/06 – 05/18/08
Combined MR and Optical Imaging System for Noninvasive Tumor Characterization and Quantification of
Oxygenation Gain Factor in a Breast Cancer Animal Model
This study will develop a combined MR and optical imaging system to improve tumor characterization and
diagnosis using animal tumor models
Role: Co-Investigator
R21/33 CA101139
Nalcioglu O. (PI)
04/16/04 – 03/31/09
NIH/NCI
Combined MR-Diffuse Optics for Functional Imaging
The aim is to construct am MR-compatible optical spectroscopic tomography system for improved spatial
localization of optical measurements and accurate optical-MRI co-registration.
Role: Co-Investigator
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page